CAS: 15205-15-9; 2-Chloro-6-Fluorobenzylamine

相似化合物

66073-54-9 916420-66-1 518357-44-3

上下游产品

CAS号668-45-1 2-氯-6-氟苯腈 | CAS号55117-15-2 2-氯-6-氟氯苄

📜2-氯-6-氟氯苄置于氨体系中,用 苯 用作溶剂,化学反应生成2-氯-6-氟苄胺
参考文献:Process For Preparation Of 9-(Dihalobenzyl) Adenines
标题:Process For Preparation Of 9-(Dihalobenzyl) Adenines
摘要:9-(二卤苄基)腺嘌呤是通过一系列温和的转化从4,5,6-三氨基嘧啶开始制备的,且不受其他位置异构体的污染,然后通过7-(N-甲酰-N-二卤苄基)氨基[1,2,5]噻二唑并进.所得化合物具有抗球虫活性,在少量情况下投与动物,特别是家禽,通常与动物饲料混合使用,对控制盲肠和/或肠球虫病很有用.

专利信息

专利号:US-2018273571-A1
优先权日:2015-01-08
标 题 :Concise synthesis of urea derivatives of amphotericin b

专利号:EP-3242554-A1
优先权日:2015-01-08
标题:Concise synthesis of urea derivatives of amphotericin b

专利号:WO-2016112260-A1
优先权日:2015-01-08
标题 :Concise synthesis of urea derivatives of amphotericin b

专利号:AU-2016205187-A1
优先权日:2015-01-08
标题 :Concise synthesis of urea derivatives of amphotericin B

专利号:US-6489364-B2
优先权日:1997-04-04
标题:Antiviral protease inhibitors
发明人：CLASSON BJORN; KVARNSTROM INGEMAR SVEN-ANDERS; SAMUELSSON BENGT BERTIL
权利人:MEDIVIR AB
摘要:Compounds of formula (I), wherein A' and A'' are independently the same or different group of formula (II) wherein: R' is H, CH3, C(CH3)2, -ORa, -N(Ra)2, -N(Ra)ORa or -DP; R''' is H or CH3; Ra is H, C1-C3 alkyl; D is a bond, alkylene, -C(=O)-, -S(O)- or S(O)2-; P is an optionally substituted, mono or bicyclic carbo- or hetereocycle; R'' is H, any of the sidechains found in the natural amino acids, carboxacetamide, or a group (CH2)nDP; M is a bond or -C(=O)N(R''')-; Q is absent, a bond, -CH(OH)- or CH2-; or R'' together with Q, M and R' define an optionally substituted 5 or 6 membered carbo- or heterocyclic ring which is optionally fused with a further 5 or 6 membered carbo- or heterocyclic ring; with the proviso that R' is -ORa, -, N(Ra)2, -N(Ra)ORa or -DP, if M is a bond and Q is absent; X is H, OH, OCH3, Y is H, OH, OCH3, but X and Y are not both H; Z' and Z'' are independently -(CH2)mP where P is as defined above; n and m are independently 0, 1 or 2; and pharmaceutically acceptable salts and prodrugs thereof have utility as aspartyl protease inhibitors of HIV. They can be prepared in a facile two step synthesis from novel 2,5-di-O-benzyl-L-mannaro-1,4:6,3-dilactone intermediates.